Phaseline

Companies › Merus

Merus: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MCLA-129
bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases
EGFR, METPhase 1Non-Small Cell Lung Cancer Metastatic–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04868877MCLA-129Phase 1Non-Small Cell Lung Cancer MetastaticOncologyOct 2026

Targets

EGFR (1) MET (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Betta Pharmaceuticals Allist Pharmaceuticals Dizal Pharmaceuticals Pierre Fabre Medicament Jiangsu Hansoh Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.